🇺🇸 FDA
Pipeline program

MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF

MSC-NTF-002-HMO-CTIL

Phase 2 mab completed

Quick answer

MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF for Amyotrophic Lateral Sclerosis is a Phase 2 program (mab) at BRAINSTORM CELL THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRAINSTORM CELL THERAPEUTICS INC.
Indication
Amyotrophic Lateral Sclerosis
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials